Maintenance therapy with the PARP inhibitor olaparib (Lynparza) extends progression-free survival by an unprecedented three years in women with advanced ovarian cancer and a BRCA mutation, results from the phase 3 SOLO-1 trial show. Presented at the European Society for Medical Oncology (ESMO) Congress in Munich, results from the study suggest a 70% lower risk of disease ...
Olaparib offers 3-year benefit in BRCA advanced ovarian cancer
By Michael Woodhead
24 Oct 2018